News & Events

Latest news & events at NeRRe Therapeutics.

NeRRe Therapeutics appoints Andrew Kay as Chairman of the Board

Stevenage, UK, September 27th 2017 – NeRRe Therapeutics, which is developing a unique portfolio of neurokinin (NK)-1 receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity, has appointed Andrew Kay as Chairman of the Board. Mr. Kay, who has extensive product development and commercial experience across the pharma and biotechnology sectors, takes over from Dr Kaasim Mahmood of Advent, who remains on the Board. Following the demerger of KaNDy Therapeutics, announced today, NeRRe Therapeutics is primarily focused on its lead product orvepitant, which is in a multinational Phase IIb trial for chronic refractory cough.

Read More

KaNDy Therapeutics launched to advance a breakthrough treatment in Women’s Health

First-in-class once daily NT-814 spun out of NeRRe Therapeutics into new company

Stevenage, UK, 27th September 2017 – KaNDy Therapeutics has been launched today to maximise the value of NT-814, a potential breakthrough medicine for the treatment of chronic debilitating Women’s Health conditions and is backed by internationally recognised life sciences investors: Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed Advisors.
NT-814 is a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal vasomotor symptoms (PMVMS). NT-814 has been spun out of NeRRe Therapeutics Holdings Ltd into KaNDy Therapeutics Ltd a separate legal entity.

Read More

NeRRe Therapeutics appoints Dr Steve Pawsey as Chief Medical Officer

NeRRe Therapeutics, is pleased to announce the appointment of Dr Steve Pawsey as Chief Medical Officer. Dr Pawsey, an anaesthetist by training, has extensive experience in the global pharmaceutical and biotechnology sector, having worked in clinical development roles for over 20 years. He will lead the progress of NeRRe’s two lead NK receptor antagonists, orvepitant and NT-814, towards late-stage clinical development, for which activity an oversubscribed £23m fundraising was recently announced.

Read More